Sai Life

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE570L01029
  • NSEID: SAILIFE
  • BSEID: 544306
INR
870.00
3.2 (0.37%)
BSENSE

Dec 05

BSE+NSE Vol: 18.34 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Neuland Labs.
Astrazeneca Phar
ERIS Lifescience
Natco Pharma
Sai Life
Jubilant Pharmo
Alembic Pharma
Caplin Point Lab
Cohance Life
Concord Biotech
OneSource Speci.
Why is Sai Life Sciences Ltd ?
1
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.25 times
2
Healthy long term growth as Operating profit has grown by an annual rate 87.31%
3
With a growth in Net Profit of 42.11%, the company declared Very Positive results in Sep 25
  • The company has declared positive results for the last 3 consecutive quarters
  • OPERATING CF(Y) Highest at Rs 330.35 Cr
  • OPERATING PROFIT TO INTEREST(Q) Highest at 15.60 times
  • NET SALES(9M) Higher at Rs 1,613.40 cr
4
With ROE of 7.5, it has a Very Expensive valuation with a 7.9 Price to Book Value
  • Over the past year, while the stock has generated a return of 0.00%, its profits have risen by 82%
5
High Institutional Holdings at 52.43%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
  • Their stake has increased by 16.21% over the previous quarter.
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Sai Life should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Icon
No Data Found
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
19.10%
EBIT Growth (5y)
87.31%
EBIT to Interest (avg)
2.36
Debt to EBITDA (avg)
1.56
Net Debt to Equity (avg)
0.03
Sales to Capital Employed (avg)
0.68
Tax Ratio
25.14%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
52.43%
ROCE (avg)
11.61%
ROE (avg)
8.71%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
105
Industry P/E
34
Price to Book Value
7.93
EV to EBIT
69.30
EV to EBITDA
46.93
EV to Capital Employed
7.76
EV to Sales
11.16
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
11.20%
ROE (Latest)
7.53%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
RSI
No Signal
Bollinger Bands
Mildly Bullish
KST
Dow Theory
No Trend
OBV
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

23What is working for the Company
OPERATING CF(Y)

Highest at Rs 330.35 Cr

OPERATING PROFIT TO INTEREST(Q)

Highest at 15.60 times

NET SALES(9M)

Higher at Rs 1,613.40 cr

PBT LESS OI(Q)

At Rs 96.72 cr has Grown at 34.4% (vs previous 4Q average

PAT(Q)

At Rs 83.84 cr has Grown at 37.4% (vs previous 4Q average

-2What is not working for the Company
DPS(Y)

Lowest at Rs 0.00

DPR(Y)

Lowest at 0.00%

Loading Valuation Snapshot...
Here's what is working for Sai Life
Net Sales - Latest six months
At Rs 1,033.89 cr has Grown at 53.11%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very positive

Net Sales (Rs Cr)

Operating Cash Flow - Annually
Highest at Rs 330.35 Cr and Grown
each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (Rs Cr)

Operating Profit to Interest - Quarterly
Highest at 15.60 times
in the last five quarters
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 96.72 cr has Grown at 34.4% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 71.99 Cr
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 83.84 cr has Grown at 37.4% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 61.02 Cr
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Here's what is not working for Sai Life
Dividend per Share (DPS) - Annually
Lowest at Rs 0.00
in the last five years
MOJO Watch
Company is distributing lower dividend than previous years

DPS (Rs)

Dividend Payout Ratio (DPR) - Annually
Lowest at 0.00%
in the last five years
MOJO Watch
Company is distributing lower proportion of profits generated as dividend

DPR (%)

Non Operating Income - Quarterly
Highest at Rs 15.33 cr
in the last five quarters
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating Income